CTLA4 Matched Antibody Pair (314) (APMAB-314LY)

Ariyarathna, H., Thomson, N. A., Aberdein, D., Perrott, M. R., & Munday, J. S. (2020). Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours. Veterinary Immunology and Immunopathology, 230, 110142.

Xu, H., Tan, P., Zheng, X., Huang, Y., Lin, T., Wei, Q., ... & Yang, L. (2019). Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis. Drug Design, Development and Therapy, 13, 2215.

Schwab, C., Gabrysch, A., Olbrich, P., Patiño, V., Warnatz, K., Wolff, D., ... & Grimbacher, B. (2018). Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects. Journal of Allergy and Clinical Immunology, 142(6), 1932-1946.

De Bruyne, M., Bogaert, D. J., Venken, K., Van den Bossche, L., Bonroy, C., Roels, L., ... & Dullaers, M. (2018). A novel LPS-responsive beige-like anchor protein (LRBA) mutation presents with normal cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and overactive TH17 immunity. Journal of Allergy and Clinical Immunology, 142(6), 1968-1971.

Kassardjian, A., Shintaku, P. I., & Moatamed, N. A. (2018). Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. PloS one, 13(4), e0195958.

Le Coz, C., Nolan, B. E., Trofa, M., Kamsheh, A. M., Khokha, M. K., Lakhani, S. A., ... & Romberg, N. (2018). Cytotoxic T-lymphocyte-associated protein 4 haploinsufficiency-associated inflammation can occur independently of T-cell hyperproliferation. Frontiers in immunology, 9, 1715.

Eliana, F., Suwondo, P., Asmarinah, A., Harahap, A., Djauzi, S., Prihartono, J., & Pemayun, T. G. D. (2017). The role of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene, thyroid stimulating hormone receptor (TSHR) gene and regulatory t-cells as risk factors for relapse in patients with Graves disease. Acta Med Indones, 49(3), 195-204.

Cho, H., Kang, H., Lee, H. H., & Kim, C. W. (2017). Programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis. International Journal of Molecular Sciences, 18(7), 1517.

Lingel, H., Wissing, J., Arra, A., Schanze, D., Lienenklaus, S., Klawonn, F., ... & Brunner-Weinzierl, M. C. (2017). CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation. Cell Death & Differentiation, 24(10), 1739-1749.

Fattah, S. A., Ghattas, M. H., Saleh, S. M., & Abo-Elmatty, D. M. (2017). Cytotoxic T-lymphocyte-associated protein 4 gene polymorphism is related to rheumatoid arthritis in Egyptian population. Archives of Physiology and Biochemistry, 123(1), 50-53.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Rabbit Anti-CTLA4 Recombinant Antibody (060)

Armenian Hamster Anti-CTLA4 Recombinant Antibody (CBYY-C2242)

Syrian hamster Anti-CTLA4 Recombinant Antibody (CBFYC-2390)

Mouse Anti-CTLA4 Recombinant Antibody (9D9)

Mouse Anti- CTLA4 Recombinant Antibody (BN13)

Mouse Anti-CTLA4 Recombinant Antibody (CBFYC-2392)

Rabbit Anti-CTLA4 Recombinant Antibody (C7862)

Mouse Anti-CTLA4 Recombinant Antibody (CBFYC-0293)

Human Anti-CTLA4 Recombinant Antibody (CBFYC-2389)

Mouse Anti-CTLA4 Recombinant Antibody (06)

Isotype control